menu search

Akari therapeutics announces establishment of boston u.s. headquarters office to support expanding operations and start of registrational phase 3 clinical trials

NEW YORK and LONDON, Aug. 18, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced...

August 18, 2023, 12:00 pm

Why shares of mesoblast are plunging friday

Mesoblast focuses on therapies to treat autoimmune disorders. The company's resubmission of Ryoncil was...

August 4, 2023, 2:46 pm

Zenas biopharma announces publication of phase 2 study of obexelimab, an investigational treatment for igg4-related disease (igg4-rd), in the lancet rheumatology

Study found obexelimab produced rapid, strong, and sustained clinical improvement, including complete clinical remission, in most patients with active...

August 1, 2023, 12:23 pm

Gracell biotechnologies to report second quarter 2023 financials on monday, august 14, 2023

SAN DIEGO and SUZHOU, China and SHANGHAI, China, July 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a glob...

July 31, 2023, 4:02 pm

Fate therapeutics to webcast conference call reporting second quarter 2023 financial results

SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage ...

July 28, 2023, 12:00 pm

Xencor to host second quarter 2023 financial results webcast and conference call on august 3, 2023

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytoki...

July 27, 2023, 8:01 am

Monte rosa therapeutics appoints dr. anthony m. manning to board of directors

BOSTON, July 26, 2023 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molec...

July 26, 2023, 11:30 am

Exagen to announce second quarter 2023 financial results on august 7, 2023

SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune...

July 25, 2023, 4:05 pm

Biosimilar contract manufacturing market size to hit usd 26.1 billion by 2032 at 18.90% cagr – report by market research future (mrfr)

Biosimilar Contract Manufacturing Market Trends and Insights By Product (Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins),...

July 24, 2023, 11:34 am

Annexon to report archer phase 2 trial results in geographic atrophy at asrs 2023

Company to hold investor conference call on Monday, July 31, 2023 at 1:30 p.m. PT / 4:30 p.m. ET BRISBANE, Calif., July 24, 2023 (GLOBE NEWSWIRE) — ...

July 24, 2023, 10:30 am

Why shares of argenx jumped this week

Argenx has only two approved therapies, Vyvgart and Vyvgart Hytrulo. Vyvgart Hytrulo fared well in a trial to treat adults with chronic inflammatory d...

July 21, 2023, 1:17 pm

Cymabay's seladelpar: an exceptional ppar agonist candidate for pbc

CymaBay Therapeutics' primary candidate, seladelpar, shows promising results as a potential treatment for primary biliary cholangitis, a liver ...

July 20, 2023, 6:50 am

Argenx to report half year 2023 financial results and second quarter business update on july 27, 2023

July 20 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of peop...

July 20, 2023, 1:00 am

Kiniksa pharmaceuticals: autoimmune therapy offers attractive prospects at current price

Innovations in the drug lineup, including ARCALYST, KPL-404, and Mavrilimumab, showcase Kiniksa's dedication to targeting challenging ...

July 19, 2023, 3:25 pm

Why shares of cabaletta bio are up tuesday

The clinical-stage biotech has seven programs in its pipeline. Cabaletta focuses on therapies to treat autoimm...

July 18, 2023, 2:58 pm

Why argenx stock is on fire today

Argenx's flagship autoimmune drug hit the primary endpoint in a registrational trial for a progressive ...

July 17, 2023, 1:02 pm

Baudax bio (bxrx) up 125% on acquiring teraimmune

Baudax Bio (BXRX) soars on the acquisition of a private company, TeraImmune. The acquisition will help advance novel cell therapies for ...

July 3, 2023, 12:57 pm

Why is baudax bio (bxrx) stock up 130% today?

Against a broadly positive backdrop due to cooling inflation data, Baudax Bio (NASDAQ: BXRX ) nevertheless managed to resoundingly steal the spotlight...

June 30, 2023, 2:01 pm

Baudax bio shares jump on acquisition of teraimmune

Shares of Baudax Bio BXRX, -1.85% jumped 25% premarket on Friday after the company announced the acquisition of TeraImmune, a privately held biotech d...

June 30, 2023, 8:18 am

: pfizer’s alopecia drug for teens and adults approved by fda

Pfizer Inc. PFE said late Friday that its drug ritlecitinib, sold under the brand name of Litfulo, has been approved by the U.S. Food and Drug Adminis...

June 23, 2023, 10:02 pm


Search within

Pages Search Results: